Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

NCT01930188 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1231

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: sitagliptin
DRUG: placebo
DRUG: placebo

Sponsor

Novo Nordisk A/S